Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease Post author: Post published:April 25, 2024 Post category:uncategorized Funding represents the first time the foundation has taken an equity position in a breath diagnostics company. You Might Also Like KFF Health News’ ‘What the Health?’: Federal health work in flux March 20, 2025 New toolkit aims to help U.S. hospitals spot deadly viral hemorrhagic fevers faster and safer October 30, 2024 Second-line treatment for drug-resistant tuberculosis is as effective as first-line medicines February 27, 2024
New toolkit aims to help U.S. hospitals spot deadly viral hemorrhagic fevers faster and safer October 30, 2024
Second-line treatment for drug-resistant tuberculosis is as effective as first-line medicines February 27, 2024